Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis

Fig. 6

(Zn-Adenine)@Ab@lncRNA LEF1-AS1 mitigated joint injury in a rat model by targeting the miR-30-5p/PIK3R2 pathway. A Protocol for a therapeutic regimen with CIA rats (n = 6 each). B–C X-ray images, H&E-stained sections, and safranin O/fast green-stained sections of the hind limbs of RA rats. D Synovium hyperplasia, cartilage damage, and inflammatory cellular infiltration for each group. E The changes in heart, liver, spleen, lung, and kidneys of rats 72 days after injection of the NPs. F Joint diameters of the indicated groups. G Arthritis score in the indicated groups. H PIK3R2 mRNA levels in the synovial tissues of the indicated groups. I–J Immunoblot showing PIK3R2, PI3K, p-PI3K, AKT, and p-AKT protein levels in the synovial tissues in each group. K Serum levels of IL-1β, IL-6, TNF-α, and IL-10. Experiments were repeated thrice (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us